| Rettig, Matthew B |
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC |
|
|
| Active, not recruiting | 3 | 1145 | Europe, Canada, Japan, US, RoW | 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT | Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc. | Prostatic Neoplasms | 07/25 | 02/26 | | |
|
NCT02881242: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 2 | 14 | US | Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist | Jonsson Comprehensive Cancer Center, Stand Up To Cancer, Novartis, Prostate Cancer Foundation | Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer | 01/24 | 01/25 | | |
CHOMP, NCT04104893: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation |
|
|
| Recruiting | 2 | 30 | US | Pembrolizumab, Keytruda | VA Office of Research and Development, Merck Sharp & Dohme LLC | Metastatic Castration Resistant Prostate Cancer | 03/25 | 12/25 | | |
| Recruiting | 2 | 100 | US | Carboplatin, Paraplatin, Olaparib, Lynparza | VA Office of Research and Development | Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations | 08/25 | 08/25 | | |
SNARE, NCT05593497: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss |
|
|
| Recruiting | 2 | 30 | US | Capivasertib, abiraterone acetate | VA Office of Research and Development | High-Risk Prostate Cancer | 05/27 | 08/27 | | |
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects |
|
|
| Active, not recruiting | 2 | 70 | US | Olaparib, Lynparza, Abiraterone Acetate, Prednisone | Northwestern University, AstraZeneca, National Cancer Institute (NCI) | Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer | 12/26 | 01/27 | | |
NCT06084338: Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc |
|
|
| Recruiting | 2 | 60 | US | stereotactic ablative radiotherapy, SBRT, Pluvicto, Lu177-PSMA, topical testosterone, androgel | VA Office of Research and Development | Prostate Cancer | 11/27 | 12/28 | | |
| Recruiting | 1/2 | 30 | US | INKmune | Inmune Bio, Inc. | Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC | 05/25 | 11/25 | | |
NCT03386071: Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib |
|
|
| No Longer Available | N/A | | NA | Trametinib 2 mg | Jonsson Comprehensive Cancer Center, Novartis | Progressive Metastatic Castrate Resistant Prostate Cancer | | | | |
NCT05435495: Mechanisms of Resistance to PSMA Radioligand Therapy |
|
|
| Recruiting | N/A | 125 | US | Single-photon emission computed tomography, SPECT/CT, Blood Draw, Tumor Biopsy, Biopsy | University of California, San Francisco, National Cancer Institute (NCI), Prostate Cancer Foundation | Prostate Cancer | 12/25 | 12/25 | | |
NCT06682390: Role of Race in Nutritional Approach in Men on ADT |
|
|
| Recruiting | N/A | 70 | US | Hypocaloric anti-inflammatory diet | University of California, Los Angeles, National Comprehensive Cancer Network | Prostate Cancer Metastatic Disease | 11/25 | 11/25 | | |
| Weintrob, Amy |
GLORI, NCT04036058: Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA |
|
|
| Active, not recruiting | N/A | 10 | US | Universal gloving, Expanded barrier precautions | VA Office of Research and Development, University of Wisconsin, Madison | Clostridium Difficile | 12/23 | 09/24 | | |
| Chapman, Julie C |
NCT04820881: Cerebrovascular Reactivity and Oxygen Metabolism as Markers of Neurodegeneration After Traumatic Brain Injury |
|
|
| Recruiting | N/A | 60 | US | | Washington D.C. Veterans Affairs Medical Center, Henry M. Jackson Foundation for the Advancement of Military Medicine | Neurodegenerative Diseases | 09/24 | 09/24 | | |
| Completed | N/A | 91 | US | | VA Office of Research and Development, Oak Ridge National Laboratory, Johns Hopkins University | Brain Concussion, Posttraumatic Stress Disorder, Dementia | 01/24 | 01/24 | | |
| Spain, Rebecca |
NCT03161028: Lipoic Acid for Progressive Multiple Sclerosis (MS) |
|
|
| Completed | 2 | 115 | Canada, US | Lipoic acid, Alpha-lipoic acid, Placebo | VA Office of Research and Development | Multiple Sclerosis | 12/23 | 06/24 | | |
| Drapalski, Amy Lynne |
NCT06580470: Improving Functioning Among Aging Women Veterans |
|
|
| Not yet recruiting | N/A | 48 | US | Tailored Cognitive Behavioral Therapy for Menopause, Tailored CBT-Meno | VA Office of Research and Development | Menopause | 12/27 | 12/28 | | |
| Harris-Love, Michael |
| Active, not recruiting | N/A | 136 | US | Eccentric Exercise, Negative work training, Concentric Exercise, Conventional strength training | VA Office of Research and Development | Sarcopenia | 08/22 | 09/23 | | |
EMPHASIS, NCT06607913: Exercise and Monitoring With Post-Hospitalization Muscle Atrophy to Sustain Intrinsic Capacity and Strength |
|
|
| Not yet recruiting | N/A | 250 | US | Exercise | VA Office of Research and Development | Chronic Kidney Disease (CKD) | 09/28 | 09/29 | | |
| Ascensao, Joao |
| Recruiting | 2 | 100 | US | Carboplatin, Paraplatin, Olaparib, Lynparza | VA Office of Research and Development | Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations | 08/25 | 08/25 | | |
| Quinones, Mercedes |
MOVE-OK, NCT05035810: A Pragmatic Trial to Determine the Benefit of Behaviorally Enhanced Exercise Incentives and Corticosteroid Injections in Osteoarthritis of the Knee Marching On for Veterans With Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 221 | US | Social Incentives and Gamification to Promote Exercise, Corticosteroid Injection given in A-B order, No Social Incentive applied, Procedure: Corticosteroid Injection given in B-A order | VA Office of Research and Development | Osteoarthritis of the Knee | 11/24 | 12/25 | | |
| Liappis, Angelike |
| Recruiting | 4 | 880 | US | Rifampin, Riboflavin Placebo | VA Office of Research and Development | Osteomyelitis, Diabetes, Amputation | 09/25 | 09/25 | | |
| Fiotto, Jade |
| Recruiting | 3 | 2540 | US | Metoprolol Succinate, Carvedilol | VA Office of Research and Development | End-Stage Kidney Disease, End-Stage Renal Disease | 11/25 | 12/27 | | |
| Little, John T |
DOORwaY90, NCT04736121: Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients |
|
|
| Active, not recruiting | N/A | 100 | US | Resin microspheres containing yttrium-90 (Y-90) | Sirtex Medical, Bright Research Partners | Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | 10/25 | 12/26 | | |
| Gollie, Jared M |
| Recruiting | N/A | 52 | US | Minimal-Dose Home-Based Resistance Exercise | VA Office of Research and Development | Long COVID | 06/25 | 06/25 | | |
NCT04397159: Effects of Combination Exercise on Fatigability in Veterans With Chronic Kidney Disease |
|
|
| Recruiting | N/A | 30 | US | Combination Exercise, Flywheel Resistance Plus Aerobic Exercise | VA Office of Research and Development | Chronic Kidney Disease Predialysis | 04/26 | 04/26 | | |
| Wyrwa, Anna |
| Recruiting | 4 | 880 | US | Rifampin, Riboflavin Placebo | VA Office of Research and Development | Osteomyelitis, Diabetes, Amputation | 09/25 | 09/25 | | |
| Recruiting | 2b | 126 | US | Phage Therapy, Placebo | Adaptive Phage Therapeutics, Inc., United States Department of Defense | Osteomyelitis, Diabetic Foot Osteomyelitis | 04/24 | 12/24 | | |
diSArm, NCT05184764: Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia |
|
|
| Recruiting | 1/2 | 50 | US, RoW | AP-SA02, Placebo | Armata Pharmaceuticals, Inc., United States Department of Defense | Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus | 12/24 | 03/25 | | |
| Taub, Daniel D |
| Completed | N/A | 91 | US | | VA Office of Research and Development, Oak Ridge National Laboratory, Johns Hopkins University | Brain Concussion, Posttraumatic Stress Disorder, Dementia | 01/24 | 01/24 | | |
| Rones, Julie |
CBT Mobile-V, NCT04002063: Does Adding a Tailored Cognitive Behavioral Therapy (CBT) Mobile Skills App Mediate Rates of Depression |
|
|
| Completed | N/A | 30 | US | CBT MobileWork-V plus CBT, CBT alone, CBT-D | VA Office of Research and Development, Corporal Michael J. Crescenz VA Medical Center | Depression | 03/24 | 03/24 | | |
| Jain, Maneesh |
| Recruiting | 2 | 100 | US | Carboplatin, Paraplatin, Olaparib, Lynparza | VA Office of Research and Development | Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations | 08/25 | 08/25 | | |
| Not yet recruiting | 2 | 60 | NA | Enhertu | Washington D.C. Veterans Affairs Medical Center, Daiichi Sankyo, Cancer Research And Biostatistics, Institute for Clinical Research | Prostate Cancer Metastatic, Prostate Cancer, CRPC | 10/27 | 10/28 | | |
| Ellis, Abigail |
NCT06303778: Combining a Smartphone App With Medications to Manage Heavy Drinking |
|
|
| Not yet recruiting | N/A | 330 | US | Stand Down mobile app, Standard Care | VA Office of Research and Development | Alcohol Use Disorder (AUD) | 11/28 | 11/28 | | |
